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Reply to the Editor: 
We appreciate the comments of Drs. Hermansson, 
Konstantinov, and Aren in response to our article. 
Unfortunately, they have misread our conclusion, which 
may be summarized as follows: The case reports pre- 
sented raise concerns that the techniques of manipula- 
tion of malignant tissue during VATS procedures, 
regardless of the extent of resection, may lead to an 
increased rate of suture line occurrences; this increase 
is the result of inadequate tissue margins caused by an 
inability to palpate extent of disease. Furthermore, the 
reported cases raise concerns that disruption of tumor- 
bearing tissue with implantation within the pleural 
cavity or within chest wall incisions occurs at rates 
higher than seen during open thoracotomy and in- 
trathoracic resections. The technique they recommend 
of placing specimens into sealed bags before withdrawal 
from the chest is reasonable and may spare incisional 
contamination; however, this will not relieve concerns 
regarding inadequate margins or disruption within the 
pleural cavity. 
The morbidity and mortality of open procedures for 
the resection of intrathoracic malignant tumors are well 
documented in the literature, as is the previously 
vanishing rare problem of tumor implantation in an 
incision. Before VATS techniques are generally 
adopted, we advocate well-designed trials that will 
document both that VATS techniques are as safe as 
open techniques and that, stage for stage, VATS tech- 
niques provide 3- and 5-year survivals equal to or better 
than those achieved with open techniques. 
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Effect of milrinone on coronary artery bypass 
grafts 
To the Editor." 
The effect of vasodilators on coronary artery bypass 
grafts is always an interesting topic because the vaso- 
constriction of the grafts may cause hypoperfusion 
syndrome, which may cause a serious problem in those 
who undergo coronary artery bypass with arterial 
grafts) 
With interest, I have read the article authored by Liu 
and associates a regarding the effect of a relatively new 
vasodilator, the phosphodiesterase II I inhibitor milri- 
none, which also possesses inotropic effects. In their 
study, the authors investigated the effect of milrinone in 
the human internal thoracic artery with regard to the 
vasorelaxant effect and the role of endothelium in such 
effect. Their findings in this article are similar to our 
previous reports in pharmacology journals. 3'4 In our 
reports, we have found that milrinone has vasorelaxant 
effects against all four vasoconstrictors we tested: po- 
tassium, U46619, phenylephrine, and endothelin-1. We 
have also tested the depressant effect of milrinone on 
the contraction induced by these vasoconstrictors. 3 In 
addition, we have found that the vasorelaxant effect of 
milrinone is endothelium independent)  I am glad to 
see that these results have been reconfirmed by Liu and 
his associates. Furthermore, we have discovered that 
milrinone and nitroglycerin have a synergistic effect 
that is clinically very important, because these two 
drugs are sometimes used together in the intensive care 
unit. 
However, on the basis of our findings with regard to 
the effect and the use of milrinone, we would emphasize 
three points: (1) Relaxation of milrinone in the potas- 
sium-precontracted internal thoracic artery is complete 
at the highest concentration ( -4  log M), although the 
sensitivity to this agent is lower (less potent) than to the 
other three agents. This demonstrates the selectivity of 
the vasorelaxant effect of this vasodilator. (2) The 
inhibitory effect of milrinone in the contraction induced 
by the four important vasoconstrictors is also slightly 
selective. It was more potent in inhibition of the 
receptor-mediated (by endothelin-1 and phenyleph- 
rine) than the depolarizing agent potassium-mediated 
contraction (Fig. 1). This is shown by the more signifi- 
cant suppression effect in the contraction induced by 
endothelin-1 and phenylephrine) (3) There is a syner- 
gistic vasorelaxant effect of the phosphodiesterase II I 
inhibitor milrinone and the nitrovasodilator nitroglyc- 
erin in human conduit arteries. This effect may be 
beneficial to patients undergoing coronary artery bypass 
grafting and to other patients requiring these vasodila- 
tors. Reduced doses of the vasodilators may be suffi- 
cient to produce vasodilatation similar to that produced 
by either of them alone at higher concentrations (Fig. 
2) .4 
On the basis of this information, we would suggest 
clinical considerations and indications for the use of 
milrinone after coronary artery bypass grafting as fol- 
lows: 
1. The use of milrinone is best indicated when the 
